Urethra-sparing stereotactic body radiotherapy for prostate cancer: How much can the rectal wall dose be reduced with or without an endorectal balloon?
Björkqvist M.; Verbakel W.; Lencart J.; Linthout N.; Ozen Z.; Pérez-Moreno J.; Zilli T.; Escude L.; Miralbell R.; Dubouloz A.; Rouzaud M.; Tsvang L.
Urethra-sparing stereotactic body radiotherapy for prostate cancer: How much can the rectal wall dose be reduced with or without an endorectal balloon?
Björkqvist M.
Verbakel W.
Lencart J.
Linthout N.
Ozen Z.
Pérez-Moreno J.
Zilli T.
Escude L.
Miralbell R.
Dubouloz A.
Rouzaud M.
Tsvang L.
BioMed Central Ltd.
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042825745
https://urn.fi/URN:NBN:fi-fe2021042825745
Kokoelmat
- Rinnakkaistallenteet [27094]